Metabolic profiling of a transgenicCaenorhabditis elegansAlzheimer model.
Despite decades of research, no early-onset biomarkers are currently available for Alzheimer's disease, a cureless neurodegenerative disease afflicting millions worldwide. In this study, transgenicCaenorhabditis eleganswere used to investigate changes in the metabolome after induced expression of amyloid-β. GC- and LC-MS-based platforms determined a total of 157 differential features. Some of these were identified usingin-house(GC-MS) or public libraries (LC-MS), revealing changes in allantoin, cystathionine and tyrosine levels. SinceC. elegansis far better suited to metabolomics studies than most other model systems, the accordance of these findings with vertebrate literature is promising and argues for further use ofC. elegansas a model of human pathology in the study of AD.
Functional Genomics and Proteomics, Department of Biology, KU Leuven, Leuven, Belgium.
Roel
R
Van Assche
Functional Genomics and Proteomics, Department of Biology, KU Leuven, Leuven, Belgium.
Liesbet
L
Temmerman
Metabolomics Australia, School of Botany, University of Melbourne, Melbourne, Australia.
Daniel A
DA
Dias
Metabolomics Australia, School of Botany, University of Melbourne, Melbourne, Australia.
Berin
B
Boughton
Functional Genomics and Proteomics, Department of Biology, KU Leuven, Leuven, Belgium.
Kurt
K
Boonen
Laboratory for Aging Physiology and Molecular Evolution, Department of Biology, Ghent University, Ghent, Belgium.
Bart P
BP
Braeckman
Functional Genomics and Proteomics, Department of Biology, KU Leuven, Leuven, Belgium.
Liliane
L
Schoofs
Metabolomics Australia, School of Botany, University of Melbourne, Melbourne, Australia.
Ute
U
Roessner
Alzheimer’s disease; Amyloid-β; Caenorhabditis elegans; Metabolic profiling; Metabolomics